Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTC 004

Next Previous
Drug Profile

LTC 004

Alternative Names: LTC-004

Latest Information Update: 17 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leto Laboratories
  • Class Antineoplastics; Biological peptides; Cytokines; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 15 receptor agonists; Interleukin 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 04 Jun 2024 Phase-II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) in China (IV) (NCT06490068)
  • 31 May 2024 Efficacy and adverse events data from a phase I trial in Solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 26 Apr 2024 Letolab plans a phase I/II trial for Sarcoma (Metastatic disease, Late-stage disease, Inoperable/Unresectable) (IV) (NCT06384248)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top